Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron’s 100 Most Sustainable U.S. Companies 2023
Merck has been recognized for the third consecutive year as one of Barron's 100 Most Sustainable U.S. Companies, ranking No. 1 in the pharmaceutical sector and advancing from No. 67 to No. 29 overall. This accolade highlights Merck's commitment to social responsibility and sustainability, as expressed by Carmen Villar, vice president of Social Business Innovation. In addition to this, Merck has also received accolades from JUST Capital, CNBC, Newsweek, and Statista for its ethical operations. The evaluation was based on over 230 ESG performance indicators by Calvert Research and Management.
- Ranked No. 1 in the pharmaceutical industry by Barron's for sustainability.
- Advanced from No. 67 to No. 29 overall in Barron's rankings.
- Recognized as an industry leader by JUST Capital and CNBC.
- None.
RAHWAY, NJ / ACCESSWIRE / April 4, 2023 / Merck, known as MSD outside of the United States and Canada, has been named one of Barron's 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots in the overall rankings from last year-from No. 67 overall in 2022 to No. 29 overall in 2023.
"At Merck, we are committed to operating responsibly and moving with urgency to deliver value for patients, society and all of our stakeholders," said Carmen Villar, vice president of Social Business Innovation for Merck. "We are pleased to see the impact of our work being recognized, and we will continue to make strides toward building a healthier, safer and more sustainable world."
Earlier this year, Merck was also recognized as an industry leader among America's Most JUST Companies by JUST Capital and CNBC, and America's Most Responsible Companies by Newsweek and Statista.
Barron's worked with Calvert Research and Management (Calvert), a leader in environmental, social and governance (ESG) investing to build its list of the most sustainable U.S. companies. Starting with 1,000 of the largest publicly traded companies by market value, Calvert narrowed the list to 100 by looking at more than 230 ESG performance indicators from seven rating companies, including Institutional Shareholder Services, MSCI and Sustainalytics.
Learn more about Merck's ESG goals and progress at merck.com/company-overview/esg.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2022 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
View additional multimedia and more ESG storytelling from Merck & Co., Inc. on 3blmedia.com.
Contact Info:
Spokesperson: Merck & Co., Inc.
Website: https://www.3blmedia.com/profiles/merck-co-inc
Email: info@3blmedia.com
SOURCE: Merck & Co., Inc.
View source version on accesswire.com:
https://www.accesswire.com/747584/Merck-Ranked-No-1-in-the-Pharmaceutical-Industry-Among-Barrons-100-Most-Sustainable-US-Companies-2023
FAQ
What ranking did Merck achieve in Barron's 100 Most Sustainable U.S. Companies for 2023?
How many spots did Merck advance in Barron's ranking from 2022 to 2023?
Which organizations recognized Merck as a responsible company?
What is the focus of Merck's sustainability efforts?
What methodology did Barron's use to rank the companies for sustainability?
